Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals (Nasdaq: SNDX) will report first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET.
Access the live audio webcast and slides via the Investors Events & Presentations page or use Conference ID Syndax1Q26 with domestic dial-in 800-590-8290 or international dial-in 240-690-8800. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement stock option awards on April 1, 2026, granting up to 228,500 shares to eight new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at one year, then monthly vesting over 36 months, subject to continued service.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards granted on March 1, 2026. The company granted options to purchase up to 81,600 shares of common stock to three new employees under its 2023 Inducement Plan.
The options vest over four years: 25% after one year, then 1/48th monthly for 36 months, subject to continued service.
Syndax (NASDAQ: SNDX) reported Q4 2025 revenue $68.7M and FY2025 revenue $172.4M, driven by Revuforj net sales of $44.2M in Q4 ($124.8M FY2025) and Niktimvo net sales of $56.0M in Q4 ($151.6M FY2025).
The company had $394.1M in cash and equivalents at year-end, completed Phase 2 IPF enrollment for axatilimab, and expects 2026 R&D plus SG&A of ~$400M while targeting profitability from product and collaboration revenue.
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.
Syndax (Nasdaq: SNDX) will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.
Investors can join via the live webcast or dial in using the provided conference numbers and Conference ID. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.
A live webcast and limited-time replay will be available in the company Investor section at www.syndax.com.
Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan. The company granted options to purchase up to 11,600 shares to two new employees.
The options vest over four years: 25% after one year and the remainder monthly (1/48th) over the following 36 months, subject to continued service.
Syndax (Nasdaq: SNDX) reported preliminary, unaudited 4Q25 and full‑year 2025 results and business updates ahead of its J.P. Morgan presentation on Jan 12, 2026.
Key figures: preliminary Revuforj net revenue of $44M in 4Q25 and $125M for 2025, Revuforj net revenue up ~38% in 4Q25 vs 3Q25; preliminary Niktimvo net revenue of $56M in 4Q25 and $152M for 2025. Year‑end cash and marketable securities approx. $394M. 2026 expense outlook: R&D plus SG&A ~$400M (ex‑$50M stock comp). Several Phase 2/3 trials and access programs planned for 2026.
Syndax (Nasdaq: SNDX) and the World Orphan Drug Alliance announced a multi-regional Managed Access Program to expand patient access to Revuforj (revumenib) outside the U.S. The program will operate where local rules permit and funding is secured and launches in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa. WODA will administer named-patient supply through its network and the program will follow local regulatory and ethical frameworks. U.S. FDA approvals for Revuforj in specified relapsed/refractory KMT2A‑translocated and NPM1‑mutated acute leukemias are noted. Physicians should contact medinfo@syndax.com for details; patients must contact their physician.